National Pharmaceuticals Completes Licensing of GLB333 From Globe Labs

National Pharmaceuticals Corp. (PINK SHEETS:NFRM) or the "Company" announced today that it has completed the licensing of GLB333 from Globe Laboratories. NFRM obtained the worldwide exclusive license to the use and marketing of a cytokine that is shown to have profound effects on the management of pain due to trauma, wound, and accidents, as well as autoimmune conditions. The product under the internal name GLB333 has a different mechanism of action to current pain killers or analgesics. It helps to rebuild the damage tissues, reduces inflammatory conditions and help to regenerate good and healthy muscle and soft tissues. Globe Laboratories has worked on the biology and use of the product for several years and has spent considerable resources on its development. The license is for twenty years and carries standard terms and conditions used by other companies in this sector.